论文部分内容阅读
Continuous dopaminergic stimulation (CDS) has become the focus of the treatment strategy for Parkinsons disease (PD) that can prevent the development of dyskinesia[1].However, the currently available CDS treatment options, such as duodenal infusion of L-DOPA(Duodopa(R)) and rotigotine transdermal delivery system (Neupro(R)), are associated with disadvantages of poor compliance, high cost or varied efficacy [2,3].